Literature DB >> 2099188

Carrier design: biodistribution of branched polypeptides with a poly(L-lysine) backbone.

J A Clegg1, F Hudecz, G Mezö, M V Pimm, M Szekerke, R W Baldwin.   

Abstract

The biodistribution has been examined in mice of a range of synthetic branched polypeptides which are based on a polylysine backbone but which differ in ionic charge, side-chain structure, and molecular size. Polycationic polypeptides, regardless of their size or primary structure at the branches, were cleared rapidly from the circulation, the liver being the major site of clearance. Polypeptides with glutamic acid in the side chain, which would be amphoteric under physiological conditions, showed a significantly prolonged blood survival, and this was seen with polypeptides in the range of molecular weights of 46,000 up to 213,000. Such polypeptides provide a useful system with which to investigate the effect of structural parameters on the pharmacokinetic properties of carrier molecules and would allow the selection of candidate carriers for a variety of uses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2099188     DOI: 10.1021/bc00006a009

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  3 in total

1.  Gamma scintigraphy of 111In-labelled branched chain polypeptides (BCP) with a poly(L-lysine) backbone in mice with mammary carcinoma: effect of charge on biodistribution and tumour imaging potential.

Authors:  M V Pimm; A C Perkins; S J Gribben; G Mezö; D Gaál; F Hudecz
Journal:  Ann Nucl Med       Date:  1995-11       Impact factor: 2.668

2.  Scintigraphic evaluation of the pharmacokinetics of a soluble polymeric drug carrier.

Authors:  M V Pimm; A C Perkins; F Hudecz
Journal:  Eur J Nucl Med       Date:  1992

3.  Targeted photodestruction of human colon cancer cells using charged 17.1A chlorin e6 immunoconjugates.

Authors:  M Del Governatore; M R Hamblin; E E Piccinini; G Ugolini; T Hasan
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.